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Abstract 
The Oviedo Convention, one of the most significant documents concerning bioethics, 
represents the first legally binding text on international biomedical law and ethics.1However, 
in literature, it has been characterised as a poor document, unable to face most bioethical 
issues2 and to adequately illustrate the human rights philosophical pattern in favour of 
which it has been issued.3 One of the Convention’s most controversial articles,4Article 17 
regarding the protection of persons unable to consent to research, was met with great 
opposition and it was finally accepted with suspicion.5 The permissive character of the article 
was a major reason for the opposition.6 This work intends to explain why Article 17 is too 
permissive. It is argued that the conditions for involving incapacitated persons in biomedical 
research, specified by Article 17, are only seemingly prohibitive. In a closer examination and 
compared to equivalent articles of International Treaties, these conditions can mostly be 
characterised as too permissive and consequently, less protective. This is justified by 
considering the Article’s inadequacy to address ethical challenges in respect to key notions 
such as the consent capacity, surrogate decision-making, risk-benefits balance, advance 
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directives, participation in research in emergency circumstances and the research 
participants’ assent. It is argued that the article’s approach is too simplistic and free to 
interpretation. As such it unsafely facilitates the participation of incapacitated individuals in 
biomedical research, while the individuals’ opportunity for participation remains depended 
on their representatives and the interpretation of Article 17 instead of reflecting the 
principle of respect for autonomy. Also,the omission ofadditional conditions that could 
enhance maximally autonomous decisions, limits the value of informed consent in favour of 
the facilitation of the process concerning the selection of participants. Consequently, it 
becomes evident that Article 17 incorporates features that confirm its permissive character. 
 
Keywords: Oviedo Convention, Article 17, conditions, biomedical research, consent capacity, 
autonomy. 
 
Όροι για τη ςυμμετοχή ατόμων, ανίκανων να δϊςουν ςυγκατάθεςη, ςε βιοιατρική 
ζρευνα ςφμφωνα με το άρθρο 17 τησ Σφμβαςησ του Οβιζδο. Είναι οι όροι αυτοί 
υπερβολικά ενδοτικοί ή απαγορευτικοί; 
 
Περίληψη 
Η Σφμβαςθ του Οβιζδο, ζνα από τα ςθμαντικότερα ζγγραφα ςχετικά με τθ βιοθκικι, 
αποτελεί το πρϊτο δεςμευτικό κείμενο διεκνοφσ βιοϊατρικοφ δικαίου και θκικισ. Ωςτόςο, 
ςτθ βιβλιογραφία, ζχει χαρακτθριςτεί ωσ ζνα φτωχό ζγγραφο, ανίκανο να αντιμετωπίςει τα 
περιςςότερα βιοθκικά ηθτιματα και να απεικονίςει επαρκϊσ το φιλοςοφικό πρότυπο των 
ανκρϊπινων δικαιωμάτων υπζρ του οποίου ςυντάχκθκε. Ζνα από τα πιο αμφιλεγόμενα 
άρκρα τθσ Σφμβαςθσ, το Άρκρο 17 ςυνάντθςε ζντονθ αντίςταςθ και τελικά ζγινε αποδεκτό 
με καχυποψία. Ο ενδοτικόσ χαρακτιρασ του Άρκρου, το οποίο αφορά ςτθν προςταςία 
ατόμων που δεν μποροφν να ςυναινζςουν ςε ζρευνα, ιταν ζνασ ςθμαντικόσ λόγοσ αυτισ 
τθσ αντίςταςθσ. Η παροφςα εργαςία ςκοπεφει να εξθγιςει γιατί το Άρκρο 17 είναι 
υπερβολικά ενδοτικό. Υποςτθρίηεται ότι οι όροι για τθ ςυμμετοχι ςτθ βιοϊατρικι ζρευνα 
ατόμων με ανικανότθτα ςυναίνεςθσ, όπωσ αυτοί κακορίηονται ςτο Άρκρο 17, είναι 
φαινομενικά μόνο απαγορευτικοί. Με μια πιο προςεκτικι εξζταςθ και ςυγκριτικά με 
αντίςτοιχα άρκρα Διεκνϊν Συνκθκϊν, οι όροι αυτοί μποροφν να χαρακτθριςτοφν ιδιαίτερα 
ενδοτικοί και ςυνεπϊσ λιγότερο προςτατευτικοί. Αυτό επιβεβαιϊνεται λαμβάνοντασ υπόψθ 
τθν ανεπάρκεια του Άρκρου να απαντιςει ςε θκικζσ προκλιςεισ που αφοροφν βαςικζσ 
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ζννοιεσ όπωσ τθν ικανότθτα ςυγκατάκεςθσ, τθ λιψθ αποφάςεων μζςω εκπροςϊπων, τθν 
ιςορροπία κινδφνου-οφζλουσ, τισ διακικεσ ηωισ, τθ ςυμμετοχι ςε ζρευνα ςε περιπτϊςεισ 
ζκτακτθσ ανάγκθσ και τθν ςφμφωνθ γνϊμθ των ςυμμετεχόντων ςτθν ζρευνα. Σε αυτι τθν 
εργαςία υποςτθρίηεται ότι θ προςζγγιςθ του Άρκρου είναι απλουςτευτικι και ελεφκερθ 
ερμθνείασ. Συνεπϊσ, διευκολφνει επιςφαλϊσ τθ ςυμμετοχι ςτθ βιοϊατρικι ζρευνα ατόμων 
μθ ικανϊν να ςυναινζςουν, ενϊ θ δυνατότθτα ςυμμετοχισ  τουσ, αντί να αντικατοπτρίηει 
τθν αρχι ςεβαςμοφ τθσ αυτονομίασ, εξαρτάται από τουσ εκπροςϊπουσ αυτϊν των ατόμων 
και τθν ερμθνεία του Άρκρου 17. Επιπλζον, θ παράλειψθ πρόςκετων όρων ικανϊν να 
ενιςχφςουν αυτόνομεσ αποφάςεισ, περιορίηει τθν αξία τθσ ενθμερωμζνθσ ςυναίνεςθσ υπζρ 
τθσ διευκόλυνςθσ τθσ διαδικαςίασ επιλογισ ςυμμετεχόντων. Συνεπϊσ, γίνεται φανερό ότι 
το Άρκρο 17 ενςωματϊνει χαρακτθριςτικά που επιβεβαιϊνουν τον ανεκτικό χαρακτιρα 
του. 
 
 
1. Introduction 
The Convention for the Protection of Human Rights and Dignity of the Human Being 
with regard to the Application of Biology and Medicine: Convention on Human Rights and 
Biomedicine (ECHRB) is one of the most significant documents, in respect to bioethics, as 
itrepresents the first legally binding text on international biomedical law and ethics.7In 
literature, it has been argued that the Convention is a poor document, unable to face most 
bioethical issues8 and it does not adequately illustrate the human rights philosophical 
pattern in favour of which it has been issued.9 
Criticism was raised since the Draft Bioethics Convention was presented few years 
before it was eventually signed in 1997. One of the most controversial topics was the one 
concerning research with incapacitated persons, which constituted a major issue especially 
in the German debate.10 Article 17 of the Convention regarding the protection of persons 
not able to consent to research was met with great opposition and after extensive 
discussions and amendments, it was accepted with suspicion in the final form of the 
Convention that was signed by the European member states. The permissive character of 
                                                          
7
S. E. Salako, op. cit. 
8
M. Moril /D. Neri,op. cit. 
9
G. Hottois, op. cit. 
10
M. A. M. De Wachter, op. cit. 
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the Article was a major reason for the opposition11 and the Explanatory Report that followed 
the Convention validates to an extent the preliminary suspicion.12 
The present paper explains if such criticism was justifiable by exploring whether the 
conditions for involving persons who are not able to consent in biomedical research 
specified by the Article 17 of the Convention are too permissive or too prohibitive. Key 
notions which constitute ethical challenges in respect to the research involving persons 
unable to consent, such as the notion of consent capacity, surrogate decision-making, the 
balance between risks and benefits, advance directives, participation in research in 
emergency circumstances and the assent of research participants can either limit or facilitate 
the participation in research depending on the way these are perceived and whether they 
are taken into consideration. In order to come up with a justifiable conclusion, the paper 
explores how adequately, if at all, Article 17 illustrates these key notions in comparison to 
the literature’s approach and equivalent articles of International Treaties addressing ethical 
issues in clinical research involving incapacitated individuals. It will be argued that while 
aspects of Article 17 seem to be prohibitive, overall, it is mostly permissive. Nevertheless, 
primarily it is necessary to point out the aspects of Article 17 of the ECHRB which are under 
scrutiny in this paper. 
 
 
2. Article 17 of the ECHRB 
‘Making informed decisions about research participation is often a difficult issue for the 
general public, given the complexities of research protocols’.13Incapacity of persons to 
consent in research can further complicate the decision-making process. Albeit, it would be 
discriminative not to consider provisions to enable their participation in biomedical research. 
Prohibition of incapacitated individuals to become research participants would deprive 
themfrom potential direct health benefits or would deprive others with similar condition to 
obtain health benefit.  
                                                          
11
A. Hendriks, op. cit. 
12
G. Hottois, op.cit. 
13
R. I. Freedman, “Ethical Challenges in the Conduct of Research Involving Persons with Mental Retardation”, 
Mental Retardation, 2001, Vol. 39 (2), pp. 130. 
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International human rights instruments, as the ECHRB, aim amongst others to provide a 
protective net for the participation of individuals in medical research.14 Towards this 
direction, Article 17 of the ECHRB sets the conditions according to which persons unable to 
consent to research are eligible to participate in biomedical research. 
Briefly, the aspects of the Article which constitute the main focus of this paper require 
that, under such circumstances, participation to the research can be allowedif the results of 
the research have the potential to produce real and direct benefit to the participant’s health, 
research of comparable effectiveness cannot be carried out on individuals capable of giving 
consent, the necessary authorization under article 6 has been given specifically and in 
writing and, the individual does not object.15 The conditions stated in the Articles 16 and 6 
are taken into consideration in the first paragraph of Article 17 and they respectively refer to 
the protection of persons undergoing research16 and the protection of persons not able to 
consent.17 The points of article 6 which will be examined below are the one requiring that 
‘an intervention may be carried out for his direct benefit’, the one stating that ‘where an 
adult does not have the capacity to consent because of mental disability, disease or similar 
reason…the research subject shall as possible take part in the authorization procedure’ and 
the one stating that ‘authorization may be withdrawn at any time in the best interest of the 
person concerned’.18 
In the second paragraph of Article 17, which also takes under consideration the points 
of the first paragraph as mentioned above, it is stated that, ‘exceptionally, if the research has 
no direct benefit to the health of the individual concerned, such research may be authorized 
when research has the aim of contributing... in the scientific understanding of the individuals 
disease or to other individuals in the same age category or afflicted with the same disease, 
only if the research entails minimal risks and minimal burden for the individual concerned’.19 
                                                          
14
H. D. C. R. Abbing, “The convention on human rights and biomedicine: An appraisal of the council of Europe 
convention”, European Journal of Health Law, 1998, Vol. 5, pp. 377. 
15
Council of Europe, “Convention for the Protection of Human Rights and Dignity of the Human Being with 
Regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine”, Journal of 
Medicine and Philosophy, 2000 Vol. 25 (2), pp. 262–263. 
16
Ibid.pp. 262. 
17
Ibid.pp. 260. 
18
Ibid. 
19
Ibid.pp.263. 
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At first sight, particularly the first paragraph, can be characterised as prohibitive 
enough, especially if one considers the inevitable existence of necessary protective 
constraints. However, after detailed examination of the Article it becomes evident that it is 
too permissive. Certain points of deficiency can also justify this approach.Considering the 
language used in Article 17, the repetition of emphatic phrases, such as “only if all the 
following conditions are met *…+the results of the research have the potential to produce 
real and direct benefit real *…+ the research entails only minimal risk and minimal burden for 
the individual concerned”,20add a restrictive character to the article. However, it appears 
that there are points where the language misses the substance. And this becomes obvious 
by comparing primarily the Article 17 standards to international standards and 
recommendations for the inclusion of incapacitated persons in biomedical research. 
 
3. The Article 17 standards compared to international standards and recommendations 
for the inclusion of incapacitated persons in biomedical research 
3.1 The Code of Nuremberg and the CCPR 
The permissive character of Article 17 is evident if one compares it with the Code of 
Nuremberg and the CCPR approach to the issue of incapacitated people participation in 
research. As a response to the Second World War’s atrocities, the Code was adopted in 1947 
and it was prohibiting the involvement of incapacitated persons in non-therapeutic 
medical.21,22Similarly, ‘Article 7 of the International Covenant on Civil and Political Rights 
(CCPR) prohibits involvement of research subjects in medical and scientific experimentation 
without their consent’.23The CCPR’s different and more strict approach to the issue is also 
well observed in the “General Comment” about the meaning of Article 7 composed by ‘the 
Human Rights Committee, a body established under the CCPR and in charge of the 
supervision and control of the implementation by State Parties of their treaty obligations’24 
According to the Committee’s comment:“3. The text of article 7 allows no limitation *…+ 7. 
Article 7 expressly prohibits medical or scientific experimentation without the free consent 
                                                          
20
Ibid. pp. 262-263. 
21
Ν. Code, “The Nuremberg Code”, Trials of war criminals before the Nuremberg military tribunals under 
control council law, 1949, Vol. 10, pp. 181-182. 
22
A. Hendriks, op. cit., pp. 113. 
23
Ibid. 
24
Ibid. pp. 114. 
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of the person concerned. *…+ 21. The Committee is concerned that, in some States, non-
therapeutic research may be conducted on minors or mentally-ill patients on the basis of 
surrogate consent, in violation of the provisions of article 7”.25 
Compared to the Code and the CCPR, Article 17 of the Oviedo Convention seems to 
express a more “contemporary” approach to the notion of informed consent and the rights 
of incapacitated people.26 Article 17 does not only clearly permit incapacitated individuals to 
participate in medical research under certain conditions, but also, it does not include any 
specification about the type of research, either therapeutic or non-therapeutic.This 
approach can be seen as favourable for incapacitated individuals as it facilitates participation 
in research and consequently access to potential health benefits. Permissiveness to this 
extent can be seen as welcomed. However, by rigorously examining the conditions included 
in Article 17, one can come across with various elements that attribute to the Article an 
over-permissive character. 
 
3.2 Balance between benefits and risks 
An argument justifying the permissive character of Article 17 can be derived by 
examining the way benefits and risks are balanced or not balanced in this article. Among the 
conditions in respect to the protection of persons not able to consent to research, it is 
required the potential to produce real and direct benefit to the participant’s health or results 
capable of conferring benefit to the person concerned or other persons…, while in respect to 
risks, only minimal risk, and burden for the individual concerned is acceptable.27 
Nevertheless, the Article does not include specific definition of level of minimal risk or 
potential therapeutic benefit.Essentially, in Article 17 it has not been considered that what is 
minimal risk for one person may create greater risk for another person.28According to the 
first paragraph of Article 17, while there is explicit request for direct benefit there is no 
protective provision against any potential risk. However, even if one accepts that the 
incapacitated participant’s representative can make a sensible decision measuring benefits 
and risks, the risks for the participant can subjectively be high. In the unlike case that the 
                                                          
25
Ibid. 114-115 A. Hendriks citing: General Comment No. 20 (1992), replacing General Comment No. 7 (1982), 
as published in International Human Rights Reports 1994 Vol. 1 (2), pp. 26-28. 
26
Ibid.pp. 13. 
27
Council of Europe, op. cit., pp. 262-263. 
28
R. I. Freedman, op. cit., pp. 136. 
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participant cannot consent, it cannot be denied that he is not able to evaluate the risks 
basing the judgement on his individual perception. Also, regarding the second paragraph of 
the article, even though there is reference to both benefits and risks, there is no request for 
the benefits to outweigh the minimal risks. If such a condition existed, then it would be more 
difficult to justify involvement in research for an incapacitated individual.Further to the 
observation of ambiguity regarding the meaning of the concepts of minimal risk and 
therapeutic benefit in the Article, arguably it can be supported that the conditions are 
flexible to interpretation and this can function either against or in favour of the participant. 
In either scenario, though, this flexibility allows greater ease to involve incapacitated 
individuals in biomedical research. 
This argument is reinforced if one considers Article 18 of the Ethical Principles for 
Medical Research Involving Human Subjects in Declaration of Helsinki 2000. In this article, it 
is stated that ‘medical research involving human subjects should only be conducted if the 
importance of the objective outweighs the inherent risks and burdens to the subject’.29 Also, 
Article 17 of the ECHRB compared to the equivalent Article 18 of the Draft Additional 
Protocol to the Convention on Human Rights and Biomedicine, on Biomedical Research 2001 
in respect to the issue of benefits and risks, occurs less protective and more permissive. This 
is because Article 18 clearly sets barriers to risks by including the condition that ‘any 
consideration of additional potential benefits of the research shall not be used to justify an 
increased level of risk or burden’.30 
Furthermore, the draft 2001 Guidelines of the Council for International Organizations of 
Medical Sciences (CIOMS), among its guidelines, it states that the risk of participation in such 
research “should be no more likely and not greater than the risk attached to routine 
medicalor psychological examination of such patients’31, an approach which also represents 
an obvious threshold to the potential risks and consequently, an indisputable constraint to 
the participation in research for incapacitated individuals. 
                                                          
29
World Medical Association, ‘World Medical Association Declaration of Helsinki. Ethical principles for medical 
research involving human subjects’, Bulletin of the World HealthOrganization, 2001, Vol. 79 (4), pp. 374. 
30
Council of Europe Steering Committee on Bioethics (CDBI), Draft Additional Protocol to the Convention on 
Human Rights and Biomedicine on Biomedical Research, Europe, 2001, pp. 9. 
31
Council for International Organizations of Medical Sciences, Draft Revision of CIOMS International Ethical 
Guidelines for Biomedical Research Involving Human Subjects(1993), Tokyo-Inuyama, 2001, guideline 9, pp. 33-
34. 
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Thus, taking under consideration the above comparisons, even though Article 17 in 
exceptional cases, as those which are set in the second paragraph, places constraints which 
can reduce the number of incapacitated participants, as it requires that the beneficiaries 
should be at the same age category or afflicted with the same disease or disorder as the one 
of the participant, it becomes evident that the simplistic way that it deals with the terms of 
benefits and risks upgrades it to more permissive than equivalent official recommendations. 
 
3.3 Surrogate decision-making and advance directives 
The same simplistic approach is adopted in respect to the role of surrogates in decision-
making. Since the principle of informed consent is the leading principle for medical 
intervention and research and supports the idea of the inviolability of the human body,32 it 
would be unethical to be omitted even in circumstances of intervention or research that the 
involved subject is unable to consent. Therefore, according to the widely-accepted method 
of asking a qualified surrogate or proxy to provide consent for research participation on 
behalf of an individual who is incapable to consent33, Article 17 does include such a 
condition, as well as, it requires that the research subject shall as possible take part in the 
authorization procedure.34However, it does not include other requirements found in 
different guidelines, which can potentially limit the access to research but they can secure a 
valid informed consent which is the expression of the incapacitated person’s autonomy.35 
In particular, there is no recommendation predicting assistance for the research subject 
to take part as possible in the decision-making procedure. On one hand, there is research 
evidence that ‘surrogates often do not know, misinterpret, or disregard the perceived 
preferences of incapacitated individuals’,36 while on the other hand, the capacity to consent 
is deferent among incapacitated individuals. It cannot exist at all, but it can also be limited. 
Particularly individuals with mental retardation can be informed and trained to be able to 
comprehend their rights and responsibilities to make decision about research.37In addition, 
                                                          
32
A. Hendriks, op. cit., pp. 112. 
33
R. I. Freedman, op. cit., pp. 135. 
34
Council of Europe at footnote 15, op. cit., pp. 260. 
35
A. M. Duguet / B. Boyer-Beviere, “Consent to medical research of vulnerable subjects from the French point 
of view: the example of consent in research in the case of Alzheimer disease”, Medicine and Law, 2011, Vol. 30, 
pp. 613. 
36
R. I. Freedman, op. cit., pp. 135. 
37
Ibid. 138. 
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although the authorization may be withdrawn at any time in best interest of the person 
concerned38 who can also raise objection about the research, the concept of advanced 
directives or the option of assent39 are not taken under consideration among the conditions 
of the Article 17.  
On the contrary, the United Nations Convention on the Rights of Persons with 
Disabilities (CRPD) 200840 does include appropriate provisions related to information and 
communication so that the incapacitated individuals will be able to take part in decision-
making,41 while the Helsinki Declaration takes under consideration the incompetent 
subject’s assent to decisions when this is possible to be obtained.42,43In respect to provisions 
about advanced directives, there has been debate about their inclusion in research as they 
are expected to have relevance for advance research consent decisions.44 Their value has 
been acknowledged in the Draft Protocol on Biomedical Research 2001. In Article 18 of the 
document it is clearly stated that previously expressed wishes and objections of the research 
subject should be taken into account.45 Furthermore, the Directive (2001/20/EC) of the 
European parliament not only takes into consideration in its Article 5 previously expressed 
wishes of persons not able to consent,46 but it also gives to them direct legal effect.47 
Nevertheless, Article 17 of the ECHRB, does not address advance directives. Although Article 
9 of the ECHRB acknowledges previously expressed wishes of the patient,48,49 there is no 
reference to this article in Article 17. In addition, while in Article 17 of the ECHRB there is no 
                                                          
38
Council of Europe, op. cit. 
39
R. I. Freedman, op. cit. 
40
J. Durham / C. E. Brolan / B. Mukandi, “The Convention on the Rights of Persons with Disabilities: A 
foundation for ethical disability and health research in developing countries”, American journal of public health, 
2014, Vol. 104 (11), pp. 2037. 
41
Ibid. pp. 2039. 
42
A. M. Duguet / B. Boyer-Beviere, op. cit., pp. 616. 
43
World Medical Association, Declaration of Helsinki, Helsinki, 1964, at article 28, pp. 4. 
44
R. I. Freedman, op. cit., pp. 137. 
45
Council of Europe Steering Committee on Bioethics, op. cit., pp. 8. 
46
European Parliament and Council of the European Union, “Directive 2001/20/EC of the European Parliament 
and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions 
of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on 
medicinal products for human use”, Official Journal of the European Union, 2001, Vol. 50, pp. 8-9. 
47
S. Lötjönen, “Medical research on patients with dementia–the role of advance directives in European legal 
instruments”, European journal of health law, 2006, Vol. 13 (3), pp. 246. 
48
Ibid., pp. 242 
49
Council of Europe at footnote 29, op. cit., pp. 261. 
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reference to a right of expressing opinion for minors, in Article 18 of the Draft Protocol it is 
stated that ‘the opinion of a minor shall be taken into consideration as an increasingly 
determining factor in proportion to age and degree of maturity’.50 
One can argue that in absence of conditions as the ones mentioned above, Article 17 is 
free to interpretation. Thus, depending on the way of interpretation it can either be 
permissive or prohibitive. However, I would argue that such additional requirements 
certainlyreassure the presence of an adequate informed consent and protect the subject 
from the possibility of exploitation, but they can also restrict access to research if the 
potential participant is unable to fulfil them.In the absence of such provisions, decision-
making is facilitated as the process can be completed quicker, the selection of participants is 
simplifiedespecially because there are no requirements regarding the grade of capacity, as 
well as, additional assent on the part of the research subjectis not expected. Unless the 
potential participant objects there is no need to obtain his positive response to carry on with 
the research. 
 By limiting such conditions which can function as protective measures regarding the 
access to research and can reassure an informed consent, the limitation extents to the 
notion of informed consent and not to the access to research which. Consequently, Article 
17 becomes more permissive by omitting to incorporate such protective conditions.Yet, it 
should be noted that this approach also functions in favour of what has often been argued 
on behalf of incapacitated individuals in relation to biomedical research.That ‘the strict 
application of the principle of consent would deprive them of the beneficial effects that 
research carried out for therapeutic purposes might entail for them’.51 Thus, limited 
application of the principle of consent, as this is addressed by Article 17, can increase 
participation of individuals not able to consent. 
 
4. Does Article 17 have any evident prohibitive characteristics? 
Certainly, Article 17 does not have an absolute permissive character. This becomes 
obvious if one considers that it does not include provisions to facilitate research in 
emergency cases such as the ones considered in Article 29 of the Helsinki Declaration. In 
Article 29 of the Helsinki Declaration it is stated that for research involving subjects who are 
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physically or mentally incapable of giving consent, in the absence of available legal 
representative and in cases of emergency research, the study may proceed without 
informed consent.52 Evidently, this approach is more permissive than Article 17. 
Nevertheless, in addition to the permissive features described above, one can note 
more details that overall outweigh the prohibitive character of the Article. Initially, it should 
be mentioned that Article 17 does not define certain groups of incapacitated individuals as 
more eligible to participate in research. For example, in comparison to the recommendation 
of the National Commission on the Protection of Human Subject 1978 according to which ‘in 
research on mental disabilities, subjects should be recruited from among non-
institutionalised populations wherever possible’,53 Article 17 prevails as more permissive. 
Albeit, it is justifiable to say that it is too permissive because it does not take into account 
that certain groups of incapacitated persons, such as institutionalised patients, are more 
prone to coercion and consequently, to exploitation than others.54 
Also, Article 17 facilitates access to research since it does not take under consideration 
difficulties in decision-making that can jeopardise the process of informed consent and 
restrict the participation to research. In the absence of precautions to avoid the problem of 
therapeutic misconceptions which often characterise either the participant’s or the 
surrogate’s decision,55 it is possible for the number of incapacitated participants to increase 
because of fallacious consent referring to treatment instead of research. 
In addition, Article 17 does not include any recommendation for the assessment of decision-
making in research by investigators such as the IRBs members whose authority is predicted 
by the NBAC Report in the US.56 According to the National Institute of Mental Health (US) 
commentary on the NBAC Report ‘not all research projects proposing to involve decisionally 
impaired persons should be approved by IRBs, and…enabled to participate in research 
studies’.57 Such kind of restrictions are not included in Article 17. This fact provides further 
reasoning on why Article 17is characterized permissive since more impaired persons are 
likely to participate in biomedical researches in the absence of such restrictions. 
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5. Conclusion 
In general terms, the permissiveness of Article 17 represents a response to the generic 
demand for inclusion of people not able to consent in research. Indeed, since the adoption 
of the Nuremberg Code the involvement of individuals unable to consent in biomedical 
researches has been significantly increased and official approaches, such as the one of the 
ECHRB, have promoted this increase.  
Although the conditions included in Article 17 of the Convention seem to be prohibitive 
enough in order to prevent the absolute involvement of incapacitated persons in research, in 
a closer examination they can be described as less restrictive than those of equivalent 
guidelines. This can be justified by considering the Article’s approach in relation to benefits 
and risks. While other guidelines explicitly adopt a certain balance between benefits and 
risks, the conditions of Article 17 in relation to this issue are very simplistic and free to 
interpretation. The same simplistic approach is adopted in relation to the decision-making 
which is realistically a difficult process when the potential participant cannot make decision. 
According to the conditions, the authority is almost entirely deprived from the research 
subject since no additional considerations in relation to his advance directives or the 
possibility of his participation in the process of decision making are predicted. 
It seems that the conditions of the Article 17 represent basic restrictions without 
measuring in depth pragmatic difficulties related to the issue of involving incapacitated 
individuals in research. On one hand, people of this group are depended on their 
representatives, the law, and the interpretation of Article 17 in order to obtain an 
opportunity to participate in biomedical research instead of acquiring a chance for their 
autonomy to be respected and promoted. On the other hand, by omitting additional 
conditions that would function as gradual steps to make as possible autonomous decision, 
but would also constitute potential constraints in involving incapacitated persons in 
research, the value of informed consent is limited in practice in favour of the facilitation of 
the process concerning the selection of participants. Consequently, in the absence of such 
additional conditions, the ones that constitutethe Article 17 is justifiable to be characterised 
as too permissive. 
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